Genenta Science S.p.A.
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
GNTA | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- OLGETTINA, NO. 58, 20132 MILAN
- Website:
- https://www.genenta.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genenta Science S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
